Phase Forward re-upped its multi-year deal with contract research organization SGS Life Sciences. Specific terms of the deal were not disclosed.
The Waltham, Mass.-based clinical trial data management provider said the agreement renews a deal with the Belgian CRO first struck in 2002.
Phase Forward posted second-quarter sales of $52.5 million, up 29 percent compared with sales of $40.9 million during the same period last year; Q2 net income slipped nearly 40 percent to $2.2 million, compared with $3.7 million during the second quarter of 2008.